Navigation Links
Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients with Moderate Asthma Severity
Date:9/10/2013

signed to help address the challenges people living with a lung disease face every day. Leveraging the company's cutting edge science and leadership in chronic obstructive pulmonary disease (COPD), Boehringer Ingelheim is researching new treatment approaches where needs persist. It is the company's goal to make a difference in the lives of patients with COPD, asthma, lung cancer, idiopathic pulmonary fibrosis and other respiratory diseases.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit www.us.boehringer-ingelheim.com'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
4. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
5. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
6. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
7. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
8. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
9. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
10. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
11. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... "US Self-monitoring Blood Glucose Market" report to ... This market insight focuses on the developments ... the United States . Reimbursement analysis and the ... analyses for more than 73 SMBG meters have been ...
(Date:12/22/2014)... 2014 Cyberonics, Inc. (NASDAQ: CYBX ), ... management of epilepsy, today announced it will participate in the ... January 14, 2015, in San Francisco . ... Executive Officer, will speak at 11:00 AM Pacific Time.  A ... clicking on the Investor Relations link on the Cyberonics home ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... (Nasdaq: NVAX ) a clinical-stage vaccine company, ... of Novavax will be presenting at the Stifel Nicolaus ... 17, 2010 at 10:20am local time at the Four ... company overview, outline its competitive position and characterize Novavax,s ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ... million shares of its common stock pursuant to an effective ... Inc. is the sole book-running manager of the offering and ... to purchase up to 1,245,000 additional shares. Halozyme intends to ...
Cached Medicine Technology:Halozyme Therapeutics Announces Public Offering of Common Stock 2Halozyme Therapeutics Announces Public Offering of Common Stock 3
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping tips ... the models at LunaDress.co.uk come with big discounts, up to 80 ... can turn out to be a most exciting memory and can ... bring surprise to a wedding. On the updated fashion blog, ladies ... for a big day . , Going out with friends to ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
(Date:12/24/2014)... Epigenetics finds applications in a large number ... discovery, developmental biology, and research for metabolic and genetic ... most widely used techniques for the discovery and development ... cancer is rapidly growing worldwide. In 2012, there were ... and 32.6 million people living with cancer (within five ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... Inc. (NYSE: MYL ),today announced that its subsidiary, ... and Drug Administration (FDA) for its,Abbreviated New Drug Application ... Zaleplon Capsules are the generic version of King Pharmaceuticals,Sonata(R) ... for,the 12 months ending March 31, 2008, according to ...
... news that DuPont,s Teflon chemicals likely,contaminate area residential wells. ... level., - Private residential well contamination with PFOA ... private drinking water wells and warnings,issued to residents in ... DEEPWATER, N.J., June 9 A coalition of,environmental ...
... ALEXANDRIA, Va., June 9 The National,Community ... of,Compounding Pharmacists (IACP) are collaborating to increase ... engage in compounding.,IACP has established a satellite ... their Director of Public Affairs, Sarah R. ...
... and Good Health this Father,s Day, Nearly 40 Million ... ... 9 Families sick and tired of Dad,s raucous,snoring, incessant allergic ... Snoring Center: a unique medical practice dedicated,exclusively to the evaluation and ...
... A new study demonstrates that microRNAs can modulate the ... may play a significant role in some human cancers. ... issue of the journal Cancer Cell, is likely to ... and leukemias. , MicroRNAs (miRNAs) are small noncoding pieces ...
... way solid tumors adapt the body,s machinery to bring ... these tumors stronger. , "In a sense, these therapies ... D.V.M., Ph.D., professor of radiation oncology at Duke University ... killing many if not most tumor cells, you are ...
Cached Medicine News:Health News:New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water 2Health News:New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water 3Health News:Pharmacist Associations Partner to Increase the Voice of Pharmacy 2Health News:Stop Dad's Sleepless Nights - and the Sniffles - With the Snoring Center 2Health News:Stop Dad's Sleepless Nights - and the Sniffles - With the Snoring Center 3Health News:MicroRNA controls expression of oncogenes 2Health News:Solid tumor cells not killed by radiation and chemotherapy become stronger 2
...
Angled 45 Degrees to Right, 9.5mm blade, gently curved .5x .25mm blunt tips; Lower blade is 0.5mm longer; 14mm from mid screw to tip; (Available in left and right;) overall length 120mm; Stainless ...
16mm Slightly Curved sharp Tips; overall length 120mm; Stainless Steel...
16mm from Mid-Screw to Blunt Tips, Gently Curved Blades; overall length 120mm; Stainless Steel...
Medicine Products: